Scientific publications

Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB)

Sep 21, 2017 | Magazine: OncoImmunology

Arantza Azpilikueta, Elixabet Bolaños, Valerie Lang, Sara Labiano, Maria A Aznar, Iñaki Etxeberria, Alvaro Teijeira, Maria E Rodriguez-Ruiz, Jose L Perez-Gracia, Maria Jure-Kunkel, Juan M Zapata, Manuel S Rodriguez, Ignacio Melero


TRAF2 dependent K63-polyubiquitinations have been recently shown to connect CD137 (4-1BB) stimulation to NF-κB activation. In a search of deubiquitinase enzymes (DUBs) that could regulate such a signaling route, A20 and CYLD were found to coimmunoprecipitate with CD137 and TRAF2 complexes. Indeed, overexpression of A20 or CYLD downregulated CD137-elicited ubiquitination of TRAF2 and TAK1 upon stimulation with agonist monoclonal antibodies.

Moreover, overexpression of A20 or CYLD downregulated CD137-induced NF-κB activation in cultured cells and in gene-transferred hepatocytes in vivo, while silencing these deubiquitinases enhanced CD137 costimulation of primary human CD8 T cells. Therefore A20 and CYLD directly downregulate the signaling from a T and NK-cell costimulatory receptor under exploitation for cancer immunotherapy in clinical trials.

CITATION  Oncoimmunology. 2017 Sep 21;7(1):e1368605. doi: 10.1080/2162402X.2017.1368605. eCollection 2017.